Response to Inquiries Regarding Share Transfers

This is a courtesy message in response to the inquiries we have received and to which we cannot respond individually, as we are in a restricted communications period. 

Please see summary response to most inquiries below: 

  • When will restrictions be lifted: If your shares are eligible for sale, the restrictions on your shares will be removed the evening before the listing day. At this point, you will also have received via the Odyssey portal an account statement of your shares which you may share with your broker. Please see “Securities Law Considerations” and “Legends” section of the Shareholder FAQs for further information.
  • Are my shares restricted: The company has entered into voluntary ‘lockups’ with select shareholders. Additionally, insiders and individuals with material inside non-public information (MNPI) are restricted from selling. The company has not specifically sold shares with lockup provisions. Any and all additional restrictions would be based upon SEC ownership rules and managed by the transfer agency in conjunction with brokers. 
  • When can you move the shares to the broker: Immediately upon commencement of trading, a transfer request can be made from a brokerage to the transfer agency.
  • When can you initiate a trade: Provided your broker has a copy of your account statement showing unrestricted shares, brokerages typically initiate trades as long as the shares are in the process of being transferred. For informational purposes only: most public market trades settle 1-2 days later; brokerages execute trades based upon the ability to view shares in another account statement. A trade can traditionally be ordered as long as the shares exist and are being moved. 
  • Where can you get your account statement: In your Odyssey account. To view your share balance, update your contact information, or generate an account statement, register for online account access by navigating to: https://uslogin.odysseytrust.com.
  • When will my account statement show any/all unrestricted shares: The evening prior to the commencement of trading. 
  • If you plan to sell your shares on or shortly after the listing day: Discuss your plans with your broker and plan to initiate the transfer of shares from Odyssey immediately upon trading commencement, as well as provide a copy of your most up-to-date account statement at that time for any/all trade orders.

A detailed FAQ style document outlining the details  was also added to Odyssey portal under ‘Documents’.

Reminder: We cannot selectively communicate with individual shareholders during this restricted period. All shareholder questions and inquiries must be directed to Odyssey at [email protected].

Disclaimer: The information provided in this communication is for general informational purposes only and is not intended to constitute legal, financial, or investment advice. Individual circumstances may vary, and you should consult with your own legal, financial, or tax advisors to determine the applicability of the information to your specific situation before taking any actions. The company is not responsible for any decisions made based on the information provided herein.

Related News

Sign Up for Updates

Enter your information to receive the latest product updates and news from Turn Therapeutics.

Muhammad Zubair

Controller

Zubair, Controller, has 5+ years of accounting and finance management experience in companies ranging from medium-sized companies to pulicly traded multinationals. Zubair is a member of the Institute of Chartered Accountants of Pakistan and holds a Master’s degree in accounting & finance (Equivalent). 

Zuraiz Chaudhary, CPA

Chief Accounting Officer, VP Finance

Zuraiz, VP of Finance and Chief Accounting Officer, is a seasoned finance & accounting executive with more than a decade experience in working with PwC, EY and KPMG.  Zuraiz is a licensed CPA in California and Texas, has a bachelor’s in business administration from Asia-e University (Malaysia), is a member of the Institute of Chartered Accountants of Pakistan. Zuraiz specializes in financial reporting, SOX compliance and internal controls.

Dr. Neil Ghodadra, MD

Chief Medical Officer, Board Director

Dr. Neil Ghodadra, Board Certified Orthopedic Surgeon, joined Turn in Q3 2017. Renowned for surgical skill and orthopedic research, he graduated Magna Cum Laude from Duke University with a BS in Biology, and with Honors from Duke Medical School. His residency at Rush Medical Center focused on sports medicine, specializing in knee & shoulder surgery.

Bradley Burnam

Chief Executive Officer & Founder

Bradley Burnam, Founder & CEO, developed PermaFusion®, a patented drug delivery system, to combat his hospital-acquired skin infection. This innovation led to Hexagen™ Wound Dressing, Turn’s flagship product. Burnam, a self-taught regulatory and formulation expert, secured Turn’s first three FDA clearances solo before assembling a skilled team.

Subscribe to the Founder's Blog

Enter your information to subscribe for the latest updates from our Founder’s Blog.